Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Biomarkers, Tumor
/ analysis
Body Mass Index
Breast
/ pathology
Breast Neoplasms
/ mortality
Chemotherapy, Adjuvant
/ statistics & numerical data
Disease-Free Survival
Female
Follow-Up Studies
Humans
Mastectomy
Middle Aged
Neoplasm Recurrence, Local
/ epidemiology
Neoplasm Staging
Prognosis
Receptor, ErbB-2
/ analysis
Receptors, Estrogen
/ analysis
Receptors, Progesterone
/ analysis
Retrospective Studies
Risk Assessment
/ methods
Time Factors
Trastuzumab
/ therapeutic use
Young Adult
Body mass index
Early breast cancer
HER2
Hormone receptors
Trastuzumab
Journal
Clinical breast cancer
ISSN: 1938-0666
Titre abrégé: Clin Breast Cancer
Pays: United States
ID NLM: 100898731
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
27
01
2019
revised:
06
06
2019
accepted:
20
06
2019
pubmed:
6
8
2019
medline:
30
3
2021
entrez:
6
8
2019
Statut:
ppublish
Résumé
A reliable risk stratification on the basis of tumor biology and host factors of HER2-positive (HER2 We retrospectively evaluated 238 women with stage I to III HER2 The early recurrence rate after 3 years resulted as 4.2% (40% HR Our real-life data highlight a different risk of eBC recurrence after grouping patients according to HR status and BMI. These results might help clinicians to identify correct treatment strategies. Patients who are HR
Identifiants
pubmed: 31378534
pii: S1526-8209(19)30081-3
doi: 10.1016/j.clbc.2019.06.008
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Receptors, Estrogen
0
Receptors, Progesterone
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e89-e98Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.